Gan, Liangying
Xie, Panpan
Tan, Yan
Wei, Gang
Yuan, Xiaojuan
Lu, Zhifei
Pratt, Raymond
Zhou, Yongchun
Hui, Ai-Min
Li, Kexin
Fang, Yi
Zuo, Li
Funding for this research was provided by:
Wanbang Biopharmaceuticals
Article History
Accepted: 14 February 2022
First Online: 5 April 2022
Declarations
:
: This work was funded by Wanbang Biopharmaceuticals.
: Liangying Gan, Panpan Xie, Kexin Li, Yi Fang and Li Zuo declare no conflicts of interest related to this study. Yan Tan, Gang Wei and Ai-Min Hui are full-time employees of Shanghai Fosun Pharmaceutical Development, Co., Ltd. Zhifei Lu is a full-time employee of Beijing Fosun Pharmaceutical Development, Co., Ltd. Xiaojuan Yuan and Yongchun Zhou are full-time employees of Wanbang Biopharmaceuticals. Raymond Pratt is a full-time employee of Rockwell Medical Inc. USA and received salary and stock options.
: The single-arm study was approved by the Ethics Committee of Beijing Hospital, and the two-sequence, randomized study was approved by the Medical Ethics Committee of Peking University People’s Hospital. The studies were carried out in accordance with the ethical principles of the Helsinki Declaration and according to the guidelines of the Chinese NMPA for clinical trial application.
: The datasets analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: Not applicable.
: All participants provided written informed consent before participating in the study.
: Written informed consent was provided by the patients.
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by LG, PX, KL, YF and LZ. All authors commented on the draft of the manuscript and read and approved the final manuscript.